Prexton Therapeutics SA of Geneva, Switzerland has raised €29 million in a Series B financing round to support two Phase 2 studies of Foliglurax, an experimental compound for Parkinson’s disease that targets a positive allosteric modulator. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals
